Erhard Quebe‐Fehling

2.7k total citations · 2 hit papers
42 papers, 1.9k citations indexed

About

Erhard Quebe‐Fehling is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Erhard Quebe‐Fehling has authored 42 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Rheumatology, 12 papers in Hematology and 10 papers in Genetics. Recurrent topics in Erhard Quebe‐Fehling's work include Spondyloarthritis Studies and Treatments (14 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Autoimmune and Inflammatory Disorders Research (7 papers). Erhard Quebe‐Fehling is often cited by papers focused on Spondyloarthritis Studies and Treatments (14 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Autoimmune and Inflammatory Disorders Research (7 papers). Erhard Quebe‐Fehling collaborates with scholars based in Switzerland, United States and Germany. Erhard Quebe‐Fehling's co-authors include L. Mauriac, F. Jänicke, Dean B. Evans, Matthew J. Ellis, Andrew Coop, William R. Miller, Margaret Dugan, Baljit Singh, F. Yunus and R. Bell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of the Rheumatic Diseases.

In The Last Decade

Erhard Quebe‐Fehling

40 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 790 citations Matthew J. Ellis, Andrew Coop et al. profile →
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials

2001 520 citations Erhard Quebe‐Fehling et al. profile →

Peers

Countries citing papers authored by Erhard Quebe‐Fehling

Since Specialization

Citations

This map shows the geographic impact of Erhard Quebe‐Fehling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erhard Quebe‐Fehling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erhard Quebe‐Fehling more than expected).

Fields of papers citing papers by Erhard Quebe‐Fehling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erhard Quebe‐Fehling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erhard Quebe‐Fehling. The network helps show where Erhard Quebe‐Fehling may publish in the future.

Co-authorship network of co-authors of Erhard Quebe‐Fehling

This figure shows the co-authorship network connecting the top 25 collaborators of Erhard Quebe‐Fehling. A scholar is included among the top collaborators of Erhard Quebe‐Fehling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erhard Quebe‐Fehling. Erhard Quebe‐Fehling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab 2025 ·Therapeutic Advances in Musculoskeletal Disease ·(unknown), Martín Rudwaleit, Frank Behrens, Christopher T. Ritchlin, Daniel Peterlik, Erhard Quebe‐Fehling, Atul Deodhar	0
2	POS1115 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: SUBGROUP ANALYSES BY BASELINE SYNDESMOPHYTES AND C-REACTIVE PROTEIN STATUS 2023 ·Xenofon Baraliakos, Désirée van der Heijde, Pedro Machado, Victoria Navarro‐Compán, Lianne S. Gensler, (unknown), Erhard Quebe‐Fehling, Aimee Readie, H. Richards, Denis Poddubnyy	2
3	Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications 2022 ·Rheumatology and Therapy ·Joseph F. Merola, Iain B. McInnes, Atul Deodhar, Amit K. Dey, Nicholas Adamstein, Erhard Quebe‐Fehling, Maher Aassi, Caroline Peine, Nehal N. Mehta	23
4	Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials 2021 ·Rheumatology International ·Maxime Dougados, Uta Kiltz, Alan Kivitz, Karel Pavelká, Susanne Rohrer, (unknown), Erhard Quebe‐Fehling, Brian Porter, Zsolt Talloczy	4
5	Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1 2021 ·BMC Musculoskeletal Disorders ·Jürgen Braun, Bjoern Buehring, Xenofon Baraliakos, Lianne S. Gensler, Brian Porter, Erhard Quebe‐Fehling, Sibylle Haemmerle	8
6	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies 2020 ·Rheumatology and Therapy ·Xenofon Baraliakos, Filip Van den Bosch, Pedro Machado, Lianne S. Gensler, Helena Marzo‐Ortega, Bintu Sherif, Erhard Quebe‐Fehling, Brian Porter, Corine Gaillez, Atul Deodhar	12
7	Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies 2019 ·Arthritis Research & Therapy ·Laura C. Coates, Johan K. Wallman, Dennis McGonagle, Georg Schett, Iain B. McInnes, Philip J. Mease, Lawrence Rasouliyan, Erhard Quebe‐Fehling, Darren L. Asquith, Andreas E. R. Fasth, Luminita Pricop, Corine Gaillez	13
8	Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies 2018 ·RMD Open ·Jürgen Braun, Atul Deodhar, Robert Landewé, Xenofon Baraliakos, Corinne Miceli‐Richard, Joachim Sieper, Erhard Quebe‐Fehling, Ruvie Martin, Brian Porter, Kunal K. Gandhi, Désirée van der Heijde, (unknown)	24
9	Occurrence and Management of Cataracts in Adult Patients (pts) with Chronic Immune Thrombocytopenia (cITP) during Long-Term Treatment with Eltrombopag (EPAG): Results from the Extend Study 2017 ·Blood ·Raymond Wong, Abderrahim Khélif, Abdulgabar Salama, Mansoor N. Saleh, (unknown), Erhard Quebe‐Fehling, James B. Bussel	1
10	Exploring the Clinical Utility of Renal Safety Biomarkers during Iron Chelation Therapy in Patients with β-Thalassemia and Other Anemias 2017 ·Blood ·Maria Domenica Cappellini, Erhard Quebe‐Fehling, Céline Pallaud, Frank Dieterle, John B. Porter	2
11	Clinical relevance of health‐related quality of life outcomes with darifenacin 2008 ·British Journal of Urology ·Paul Abrams, Con Kelleher, Jasper Huels, Erhard Quebe‐Fehling, Mohamed A. Omar, Michael Steel	21
12	Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy 2008 ·International Journal of Clinical Practice ·Norman R. Zinner, Kathleen C. Kobashi, Ursula Ebinger, (unknown), (unknown), Erhard Quebe‐Fehling, Patricia Koochaki	40
13	Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. 2003 ·PubMed ·Matthew J. Ellis, Andrew Coop, Baljit Singh, Tao Yu, Antonio Llombart‐Cussac, F. Jänicke, L. Mauriac, Erhard Quebe‐Fehling, Hilary A. Chaudri‐Ross, Dean B. Evans, William R. Miller	167
14	Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women 2003 ·Menopause The Journal of The North American Menopause Society ·Alessandro Rubinacci, Elena Peruzzi, Alberto Bacchi Modena, (unknown), (unknown), Vincenzo De Leo, F. Pansini, Erhard Quebe‐Fehling, Patricia Palacios	26
15	Dose proportionality study of four doses of an estradiol transdermal system, Estradot® 2003 ·Maturitas ·Mohammad Salim Hossain, Erhard Quebe‐Fehling, (unknown), (unknown), Andrej Skerjanec, Patricia Palacios, (unknown)	11
16	Comparative bioequivalence studies with Estradot® and Menorest® transdermal systems 2003 ·Maturitas ·Mohammad Hossain, Erhard Quebe‐Fehling, (unknown), (unknown), Andrej Skerjanec, Albert Cohen, (unknown), Patricia Palacios	5
17	Comparative study to evaluate skin irritation and adhesion of Estradot® and Climara® in healthy postmenopausal women 2002 ·Climacteric ·Patricia Palacios, (unknown), (unknown), Erhard Quebe‐Fehling, Lisa K. Lockhart, (unknown)	9
18	A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease 1998 ·Respiratory Medicine ·D. Vervloët, Thommy Ekström, Riccardo Pela, (unknown), (unknown), (unknown), Erhard Quebe‐Fehling, Giovanni Della Cioppa, Giacomo Di Benedetto	44
19	Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease 1998 ·Respiratory Medicine ·Neil C. Thomson, Robert Angus, Erhard Quebe‐Fehling, (unknown)	22
20	Clinical relapse of Crohn's disease under standardized conservative treatment and after excisional surgery 1989 ·Digestive Diseases and Sciences ·(unknown), H. Goebell, K. Schaarschmidt, (unknown), Erhard Quebe‐Fehling, F. W. Eigler	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact